BCL2 and cancer: This can range from targeted protein degradation of highly overexpressed anti-apoptotic proteins in cancer cells or senescent cells, e.g., members of the BCL-2 protein family [67,68], to the delivery of transcription factors over several days for in vivo reprogramming efforts, as was recently accomplished using an mRNA-based approach [69].